Clareon IOL Retrospective Data Collection
Launched by ALCON RESEARCH · Mar 22, 2023
Trial Information
Current as of May 03, 2025
Completed
Keywords
ClinConnect Summary
In this retrospective postmarket study, the WaveTec AnalyzOR Database will be reviewed. All available data that meet the data selection criteria as of the data cutoff will be analyzed.
Gender
ALL
Eligibility criteria
- Data Selection Criteria (eyes):
- • Must have undergone cataract extraction by phacoemulsification with implantation of a Clareon UVA IOL (CC60WF, CCW0T3, CCW0T4, CCW0T5, CCW0T6, or CCA0T0) using the WaveTec ORA System.
- • Must have a BCDVA in the WaveTec AnalyzOR Database from ≥ 10 days after surgery.
- • Predicted residual refractive error spherical equivalent (SE) ≤ 0.75 D.
About Alcon Research
Alcon Research is a leading global company dedicated to advancing eye care through innovative research and development. As a subsidiary of Novartis, Alcon focuses on the development of cutting-edge products and therapies for vision correction and eye health, including surgical, pharmaceutical, and consumer eye care solutions. With a commitment to enhancing the quality of life for patients worldwide, Alcon Research conducts rigorous clinical trials to evaluate the safety and efficacy of its products, ensuring that they meet the highest standards of care. Through collaboration with healthcare professionals and institutions, Alcon remains at the forefront of ophthalmic advancements, driving progress in the field of vision science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fort Worth, Texas, United States
Patients applied
Trial Officials
Clinical Lead, Surgical
Study Director
Alcon Research, LLC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials